5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. Supplemental members is going to be enrolled with the identified monotherapy dosign regimen. In Phase B, individuals will receive oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Seg